Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

NovoCure Limited - Ordinary Shares (NQ: NVCR )

17.60 -0.17 (-0.96%)
Streaming Delayed Price Updated: 11:48 AM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NovoCure Limited - Ordinary Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
18 19 Next >
The Law Offices of Frank R. Cruz Announces Investigation of NovoCure Limited (NVCR) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
3 Small-Cap Drug Stocks to Watch as Their Clinical Trials End Soon
These three small cap drug companies could become gold or lead depending on the outcomes of their clinical trials. 
Via InvestorPlace
This Beaten-Down Growth Stock Has 99% Upside, According to Wall Street
A big turnaround could be in the cards for this medical device maker. 
Via The Motley Fool
Stock Market Rally Broadens Out; Apple Unveils Vision Pro, SEC Sues Binance, Coinbase: Weekly Review
The Nasdaq held near 52-week highs while small caps ramped up. 
Via Investor's Business Daily
The Latest Analyst Ratings for NovoCure
Via Benzinga
Why NovoCure Stock Is Crashing Today
Analysts weren't wowed by the company's late-stage data. 
Via The Motley Fool
NovoCure's Return On Capital Employed Overview
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 29 companies set new 52-week lows. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2023
Via Benzinga
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against NovoCure Limited and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
4 Analysts Have This to Say About NovoCure
Via Benzinga
Should You Buy Novocure Stock Right Now?
Most Wall Street analysts think this stock will skyrocket. They could be right. 
Via The Motley Fool
NovoCure (NVCR) Q1 2023 Earnings Call Transcript
NVCR earnings call for the period ending March 31, 2023. 
Via The Motley Fool
These 2 Nasdaq Stocks Are Plunging. Here's Why
Tuesday brought optimism to the stock market overall, but not for these companies. 
Via The Motley Fool
Dow Falls Over 100 Points; Hoth Therapeutics Shares Spike Higher
U.S. stocks traded mixed toward the end of trading, with Dow Jones dropping over 100 points on Tuesday. The Dow traded down 0.36% to 33,440.78 while the NASDAQ rose 0.09% to 13,241.04. The S&P 500,... 
Via Benzinga
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NovoCure Limited and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Stocks Mixed As VIX Extends Lows
Stocks are struggling for direction midday. 
Via Talk Markets
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 69 stocks hit new 52-week lows. 
Via Benzinga
Novocure's Cancer Treating Electric Fields Improves Survival In Lung Cancer Patients, But Stock Tumbles On Remaining Doubts
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why THOR Industries Shares Are Trading Higher By 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Recruiter.com Group, Inc. (NASDAQ: RCRT) shares jumped 114% to $0.41. Recruiter.com signed a definitive agreement for planned purchase of fintech assets of GoLogiq. 
Via Benzinga
Nasdaq Edges Higher; Joann Shares Plummet
U.S. stocks traded mixed midway through trading, with Nasdaq Composite turning higher on Tuesday. The Dow traded down 0.08% to 33,534.50 while the NASDAQ rose 0.27% to 13,265.27. The S&P 500, also... 
Via Benzinga
Coinbase, Blue Bird, Tingo Group And Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded mixed, with the Nasdaq Composite rising around 0.2% on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Novocure Crashes Almost 30% As Critics Question Its 'Profound' Impact In Lung Cancer Treatment
Novocure said its device, Optune, extended overall survival by more than three months for some lung cancer patients. 
Via Investor's Business Daily
Dow Drops 50 Points; J.M. Smucker Earnings Top Views
U.S. stocks traded lower this morning, with Dow Jones dropping around 50 points on Monday. The Dow traded down 0.16% to 33,509.87 while the NASDAQ fell 0.19% to 13,203.91. The S&P 500, also fell,... 
Via Benzinga
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
From Zai Lab Limited
Via GlobeNewswire
LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
From Novocure
Via Business Wire
Novocure Pledges $3 Million to Conquer Cancer®, the ASCO Foundation, to Support Cancer Research and Education
From Novocure
Via Business Wire
3 No-Brainer Stocks to Buy for Under $100 Right Now
These stocks might not remain under $100 for too much longer. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For May 16, 2023
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.